Current role
Nicholas A.J. Botwood
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Nicholas A.J. Botwood
Syndax Pharmaceuticals Inc reported in an 8-K filed May 16, 2025 that Nicholas A.J. Botwood was appointed Head of Research and Development, Chief Medical Officer, effective May 12, 2025.
“On May 12, 2025, the Company issued a press release announcing that Nicholas A.J. Botwood, BSC (HONS), MB BS, MFPM, FRCP, will join the Company as Head of Research and Development, Chief Medical Officer, effective May 12, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2025-05-12–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Syndax Pharmaceuticals Inc
Other people whose current roles at this company are on record from its filings.
- Michael A. Metzger CEO, Board Member
- Michael Metzger CEO
- Daphne Karydas CFO
- Keith A. Goldan CFO
- Keith Goldan CFO
- Luke J. Albrecht General Counsel
- Aleksandra Rizo, M.D., Ph.D. Board Member
- Martin H. Huber, M.D. Board Member
- Pierre Legault Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.